Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...
Potential therapeutic target for atherosclerosis found in insulin-like growth factor-binding protein 6
A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...